UroGen Pharma Ltd.

NasdaqGM:URGN Stock Report

Market Cap: US$449.0m

UroGen Pharma Balance Sheet Health

Financial Health criteria checks 4/6

UroGen Pharma has a total shareholder equity of $25.5M and total debt of $121.7M, which brings its debt-to-equity ratio to 477%. Its total assets and total liabilities are $301.9M and $276.4M respectively.

Key information

477.0%

Debt to equity ratio

US$121.71m

Debt

Interest coverage ration/a
CashUS$249.58m
EquityUS$25.52m
Total liabilitiesUS$276.43m
Total assetsUS$301.94m

Recent financial health updates

Recent updates

Is UroGen Pharma (NASDAQ:URGN) Weighed On By Its Debt Load?

Nov 18
Is UroGen Pharma (NASDAQ:URGN) Weighed On By Its Debt Load?

UroGen Pharma: There Is Some Potential Here

Aug 28

UroGen: Q3 NDA Opens Hefty Revenue Opportunity

Jun 17

UroGen Pharma Ltd.'s (NASDAQ:URGN) Share Price Boosted 35% But Its Business Prospects Need A Lift Too

Jun 14
UroGen Pharma Ltd.'s (NASDAQ:URGN) Share Price Boosted 35% But Its Business Prospects Need A Lift Too

UroGen Pharma Ltd. (NASDAQ:URGN) Looks Inexpensive After Falling 27% But Perhaps Not Attractive Enough

Apr 09
UroGen Pharma Ltd. (NASDAQ:URGN) Looks Inexpensive After Falling 27% But Perhaps Not Attractive Enough

UroGen: All Eyes On UGN-102

Mar 18

UroGen Pharma Ltd. (NASDAQ:URGN) Just Released Its Annual Results And Analysts Are Updating Their Estimates

Mar 17
UroGen Pharma Ltd. (NASDAQ:URGN) Just Released Its Annual Results And Analysts Are Updating Their Estimates

UroGen Pharma Ltd. (NASDAQ:URGN) Looks Inexpensive But Perhaps Not Attractive Enough

Jan 18
UroGen Pharma Ltd. (NASDAQ:URGN) Looks Inexpensive But Perhaps Not Attractive Enough

UroGen gets FDA nod for extending duration of Jelmyto admixture

Sep 28

Financial Position Analysis

Short Term Liabilities: URGN's short term assets ($295.1M) exceed its short term liabilities ($32.8M).

Long Term Liabilities: URGN's short term assets ($295.1M) exceed its long term liabilities ($243.6M).


Debt to Equity History and Analysis

Debt Level: URGN has more cash than its total debt.

Reducing Debt: URGN's debt to equity ratio has increased from 0% to 477% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: URGN has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if URGN has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Discover healthy companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 09:56
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

UroGen Pharma Ltd. is covered by 17 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Anita DushyanthBerenberg
Jonathan AschoffB. Riley Wealth
Jason KolbertD. Boral Capital LLC.